acknowledge these ‘special ones’: maybe by publishing their names on the College website or interviewing them for the Psychiatric Bulletin. Someone once said that ‘The most intelligent and the most competitive are the most reluctant to acknowledge their peers’. Is this the case, and if so, should it not change?

If any Laughlin Prize winner over the past 20 years wishes to contact me, I would like to repeat the survey.

Declarations of interest
S G. did not win the Laughlin Prize and the views expressed here are solely his own.

Acknowledgements
I thank all respondents.

Sanju George Consultant in Addiction Psychiatry, Birmingham and Solihull Mental Health NHS Foundation Trust, The Bridge Clinic, Larch Croft, Chelsey Wood, Birmingham B37 7UR, email: sanju.george@bmsnhs.nhs.uk

do: 10.1192/pb.33.11.438a

Is this not discrimination?
During one of the recent ward rounds, we decided to discharge a patient who had a diagnosis of schizophrenia affective disorder. He had been on the ward for about 2 months as a voluntary patient and he was treated with antipsychotic medication. We advised him that he should continue the medication on a daily basis after the discharge in order to prevent future relapse. He said that he had to pay for prescriptions and therefore expressed his difficulty in taking the antipsychotic medication on a long-term basis.

Research by Rethink (unpublished; personal communication, 2009) shows that 26% of service users currently pay for prescriptions (56% of those who have been in paid employment over the past 12 months); 38% of people with severe mental illnesses like schizophrenia have to choose between paying household bills and prescription charges (www.prescriptionpromise.org). This group of patients will now have to pay even more due to the recent increase in prescription charges, which many already cannot afford. This grossly unjust situation can result in people not getting their medicines and as a result having a relapse of their mental illness.

Patients with chronic conditions such as hypothyroidism and diabetes mellitus are receiving free medication irrespective of their job or financial background (www.rhbsa.nhs.uk/1126.aspx). Prescription charges have also been abolished recently for people with cancer, and the Parkinson’s Disease Society has now urged the government to end prescription charges in England for people with Parkinson’s disease. Why not those with enduring mental health difficulties?

Although a number of patients with chronic mental health problems do get free medication owing to their poor financial status, there are patients who may lose their money in the bank or other income. It is not fair to presume that all psychiatric patients do not have any money and all of them are not capable of generating an income or even not entitled to inherit wealth.

The ethos for providing free medication in chronic conditions such as hypothyroidism should be valid and applicable to those with long-term mental health difficulties.

The College, along with the voluntary sector, should actively campaign to put pressure on the government to abolish prescription charges for people with long-term mental illness.

*Manoj K. George Specially Registrar in Psychiatry, North Essex Partnership NHS Foundation Trust-Mental Health, The Derwent Centre, Princess Alexander Hospital, Harlow CM20 1QX, email: Manoj.George@hes.nhs, Renju Joseph Clinical Director, Consultant Psychiatrist, Dudley and Walsall Mental Health Partnership NHS Trust, Bushey Fields Hospital, Dudley
do: 10.1192/pb.33.11.439

HoNOS: does HoNOS provide a good enough measure of outcome?
Sugarman et al highlight an important aspect of mental healthcare in their paper which analyses the use of Health of the Nation Outcome Scales (HoNOS) in assessing change among psychiatric patients. Although they demonstrate that it is possible to measure outcomes using a suitable instrument, their data also reveal the limited utility of such a ‘blunt instrument’ and they provide an honest account of its shortcomings, recommending that it should not be used alone. Indeed, the tiny degrees of change indicated in their results have little meaning for real-life clinical practice.

Historically, measuring clinical outcomes in psychiatry was discarded as anathema² despite the availability of a variety of simple, quick and meaningful scales in many major conditions: the Beck Depression Inventory and the Hamilton scales for depression and anxiety being examples. It is essential that clinicians engage with the use of outcome measures, especially in light of the drive towards the use of outcomes in commissioning services, payment by results and the public availability of information about health providers that is now being published online.

A further demand, shaped by the Next Stage Review³ and various National Institute for Health and Clinical Excellence guidelines, is for measures to underpin the shared care of patients between primary and secondary care services. The concept of remission is of use here and has been well established in connection with depression⁴ but with few other mental disorders. Recent work on schizophrenia has provided a well-argued case for remission criteria to support shared care of patients with this disorder. The instrument, derived from the Positive and Negative Syndrome Scale, takes 10 minutes to administer and provides a simple, meaningful result for clinicians, patients and carers. Remission criteria have the additional advantage over HoNOS of being specific to the challenges experienced by patients with these disorders, both as an objective snapshot of the state of an individual’s illness and as a marker of their long-term stability.⁵

The use of dynamic markers such as remission scores to measure progress is actively encouraged in the World Health Organization’s Mental Health Gap Action Programme⁶ if new models of healthcare are to be evaluated properly and the engagement of stakeholders facilitated, validated assessment of patient change will need to be performed to ensure both continued success and continued funding.

1 Sugarman P, Walker I, Dickens G. Managing outcome performance in mental health using HoNOS: experience at St Andrew’s Healthcare. Psychiatr Bull 2009; 33: 285–9.
2 Jacques J. Payment by results and mental health services. Psychiatr Bull 2008; 32: 361–3.
3 Department of Health. NHS Next Stage Review Final Report TSO (The Stationery Office), 2008.
4 Frank E, Pien R, Jarrett RB, Keller MB, Kupfer DJ, Lavoni PW, et al. Conceptualisation and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 50: 407–8.
5 Yeomans D, Taylor M, Currie A, Whale R, Ford K, Fear C, et al. How long have you been well? Remission as an outcome in schizophrenia. Advar Psychiatr Treat 2009; in press.
6 World Health Organization. mhGAP: Mental Health Gap Action Programme: Scaling up Care for Mental, Neurological and Substance Use Disorders. WHO/Pre, 2008.

*Benjamin J. Sieniewicz Foundation 2 Doctor, Gloucestershire Foundation Trust, Wotton Lawn Hospital, Horton Road, Gloucester GL1 3VL, email: benjamin.sieniewicz@glos.nhs.uk, Chris Fear Consultant Psychiatrist, 2gether NHS Foundation Trust
do: 10.1192/pb.33.11.439a

Involvement of a young service user in the appointment of a doctor
The importance of involving service users in all aspects of their care has been